Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
311.43
-8.12 (-2.54%)
At close: Nov 3, 2025, 4:00 PM EST
306.70
-4.73 (-1.52%)
After-hours: Nov 3, 2025, 5:10 PM EST
Bio-Rad Laboratories Revenue
Bio-Rad Laboratories had revenue of $653.00M in the quarter ending September 30, 2025, with 0.51% growth. This brings the company's revenue in the last twelve months to $2.56B, down -0.88% year-over-year. In the year 2024, Bio-Rad Laboratories had annual revenue of $2.57B, down -3.92%.
Revenue (ttm)
$2.56B
Revenue Growth
-0.88%
P/S Ratio
3.35
Revenue / Employee
$332,143
Employees
7,700
Market Cap
8.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.57B | -104.70M | -3.92% |
| Dec 31, 2023 | 2.67B | -131.00M | -4.67% |
| Dec 31, 2022 | 2.80B | -120.35M | -4.12% |
| Dec 31, 2021 | 2.92B | 376.92M | 14.81% |
| Dec 31, 2020 | 2.55B | 233.97M | 10.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
BIO News
- 4 days ago - Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Bio-Rad Reports Third-Quarter 2025 Financial Results - Business Wire
- 10 days ago - Compelling Value In Small-Cap Equities And Select Cyclicals - Seeking Alpha
- 10 days ago - 7 Stocks Taking The Next Step To Be On Offense - Seeking Alpha
- 13 days ago - It's time to scoop up undervalued stocks in this critical sector of the economy - Market Watch
- 18 days ago - Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025 - Business Wire
- 2 months ago - Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc. - GlobeNewsWire
- 2 months ago - Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript) - Seeking Alpha